JP2012530720A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530720A5
JP2012530720A5 JP2012516346A JP2012516346A JP2012530720A5 JP 2012530720 A5 JP2012530720 A5 JP 2012530720A5 JP 2012516346 A JP2012516346 A JP 2012516346A JP 2012516346 A JP2012516346 A JP 2012516346A JP 2012530720 A5 JP2012530720 A5 JP 2012530720A5
Authority
JP
Japan
Prior art keywords
amino acids
peptide
seq
trp
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516346A
Other languages
English (en)
Japanese (ja)
Other versions
JP5908832B2 (ja
JP2012530720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/039223 external-priority patent/WO2010148335A2/en
Publication of JP2012530720A publication Critical patent/JP2012530720A/ja
Publication of JP2012530720A5 publication Critical patent/JP2012530720A5/ja
Application granted granted Critical
Publication of JP5908832B2 publication Critical patent/JP5908832B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516346A 2009-06-18 2010-06-18 構築されたウィルス性ペプチド組成物及び使用方法 Expired - Fee Related JP5908832B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21820909P 2009-06-18 2009-06-18
US61/218,209 2009-06-18
PCT/US2010/039223 WO2010148335A2 (en) 2009-06-18 2010-06-18 Structured viral peptide compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2012530720A JP2012530720A (ja) 2012-12-06
JP2012530720A5 true JP2012530720A5 (enExample) 2013-08-01
JP5908832B2 JP5908832B2 (ja) 2016-04-26

Family

ID=43357076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516346A Expired - Fee Related JP5908832B2 (ja) 2009-06-18 2010-06-18 構築されたウィルス性ペプチド組成物及び使用方法

Country Status (6)

Country Link
US (2) US9822165B2 (enExample)
EP (3) EP3698811A1 (enExample)
JP (1) JP5908832B2 (enExample)
AU (1) AU2010263056B2 (enExample)
CA (2) CA3037721A1 (enExample)
WO (1) WO2010148335A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
CA2833171C (en) 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
CN104254563B (zh) * 2012-02-24 2017-09-12 大金工业株式会社 氟橡胶组合物
WO2014144148A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
US9644002B2 (en) 2013-07-25 2017-05-09 Yale University Allosteric modulators of EGFR and constitutively active mutants
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
EP3214093A1 (en) * 2016-03-03 2017-09-06 Fondation The Ark Fusion respiratory syncytial virus inhibitors and use thereof
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
ES2935622T3 (es) 2016-08-26 2023-03-08 Dana Farber Cancer Inst Inc Polipéptidos y miméticos de bcl-w para el tratamiento o la prevención de la neuropatía periférica y la pérdida auditiva inducidas por la quimioterapia
US12344643B2 (en) 2016-12-07 2025-07-01 The University Of Chicago Compositions and methods for inhibition of FOXP3
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
WO2018200323A1 (en) 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
WO2019090015A1 (en) 2017-11-03 2019-05-09 Yale University Peptidic materials that traffic efficiently to the cell cytosol and nucleus
WO2019094830A1 (en) * 2017-11-10 2019-05-16 Washington University Mitofusin modulation agents and methods of use thereof
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (en) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
JP7727551B2 (ja) 2019-04-18 2025-08-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 構造的に安定化されたペプチドによるユビキチンおよびユビキチン様ｅ１活性化酵素の選択的標的化
WO2021126827A1 (en) 2019-12-16 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
JP7894318B2 (ja) * 2020-03-04 2026-07-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用
WO2021216845A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
US10975126B1 (en) * 2020-04-23 2021-04-13 King Faisal University MERS-CoV inhibitor peptides
AU2021262752A1 (en) 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
WO2022081827A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2022098848A1 (en) 2020-11-05 2022-05-12 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
US20240317826A1 (en) * 2021-05-11 2024-09-26 Albert Einstein College Of Medicine Compositions and methods for treating and/or identifying an agent for treating hiv-1 infections
MX2024002824A (es) 2021-09-08 2024-06-28 Dana Farber Cancer Inst Inc Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos.
EP4518900A1 (en) 2022-05-04 2025-03-12 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2025090958A1 (en) * 2023-10-27 2025-05-01 Red Queen Therapeutics, Inc. Antiviral structurally-stapled paramyxoviridae peptide-cholesterol conjugates and uses thereof
WO2026024936A2 (en) 2024-07-25 2026-01-29 Dana-Farber Cancer Institute, Inc. Bh4 domain peptides and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2270869A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
JP2003529319A (ja) 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
US20060241027A1 (en) 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
WO2005034842A2 (en) 2003-05-19 2005-04-21 Progenics Pharmaceuticals, Inc. Peptides useful as hiv fusion inhibitors
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
US8003332B2 (en) 2005-05-06 2011-08-23 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of membrane fusion proteins
US20090035707A1 (en) * 2007-08-01 2009-02-05 Yubing Wang Rheology-controlled conductive materials, methods of production and uses thereof
US20110033522A1 (en) * 2007-09-26 2011-02-10 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法

Similar Documents

Publication Publication Date Title
JP5788178B2 (ja) ウィルス感染症の治療のための組成物及び方法
AU2010263056B2 (en) Structured viral peptide compositions and methods of use
US7311916B2 (en) Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
KR102638978B1 (ko) Rsv에 대한 백신
US20090053257A1 (en) Replikin peptides and uses thereof
JP7317047B2 (ja) インフルエンザウイルスワクチン及びその使用
BR112015029635B1 (pt) Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição
EA017957B1 (ru) Композиции и способы, ингибирующие грипп
JP2021524280A (ja) ハウスダストダニアレルギーの処置および予防
CA2190972A1 (en) Compositions of transactivating proteins of human immunodeficiency virus
EP0356007A2 (en) Antigenic determinants
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
WO2025103370A1 (zh) 包含冠状病毒的保守重组蛋白片段的疫苗组合物及其应用
CN121991182A (zh) 甲型流感病毒h5蛋白突变体及其应用
Aguilar et al. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1
ZA200106535B (en) Methods of eliciting broadly neutralizing antibodies targeting HIV-1 GP41.